These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 21118641)

  • 1. [Expression and clinical significance of PML, P53 and P16INK4A in lung cancer].
    Zhao Z; Huang Q; Zhao T; Zhao J
    Zhongguo Fei Ai Za Zhi; 2007 Jun; 10(3):176-82. PubMed ID: 21118641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expression of promyelocytic leukaemia protein in lung carcinomas and clinical significance thereof].
    Zhao ZL; Huang QY; Xu S; Zhang L; Zhao HR
    Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(47):3362-6. PubMed ID: 17313836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue.
    Bova RJ; Quinn DI; Nankervis JS; Cole IE; Sheridan BF; Jensen MJ; Morgan GJ; Hughes CJ; Sutherland RL
    Clin Cancer Res; 1999 Oct; 5(10):2810-9. PubMed ID: 10537346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis.
    Dosaka-Akita H; Hu SX; Fujino M; Harada M; Kinoshita I; Xu HJ; Kuzumaki N; Kawakami Y; Benedict WF
    Cancer; 1997 Apr; 79(7):1329-37. PubMed ID: 9083154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
    Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
    Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression.
    Vonlanthen S; Heighway J; Tschan MP; Borner MM; Altermatt HJ; Kappeler A; Tobler A; Fey MF; Thatcher N; Yarbrough WG; Betticher DC
    Oncogene; 1998 Nov; 17(21):2779-85. PubMed ID: 9840942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The expression of O6-methylguanine DNA methyltransferase and p53 in non-small cell lung cancer and the association with the prognosis].
    Liu Y; Wang J; Zhang H; Fu XM; Wang HQ
    Zhonghua Jie He He Hu Xi Za Zhi; 2010 Jun; 33(6):427-31. PubMed ID: 20979814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
    De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
    Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
    Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M
    Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
    Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
    Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma.
    Burke L; Flieder DB; Guinee DG; Brambilla E; Freedman AN; Bennett WP; Jones RT; Borkowski A; Caporaso NA; Fleming M; Trastek V; Pairolero P; Tazelaar H; Midthun D; Jett JR; Liotta LA; Travis WD; Harris CC
    Clin Cancer Res; 2005 Jan; 11(1):232-41. PubMed ID: 15671551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression of fas and P53 protein in resected non-small cell lung cancer and its prognostic significance].
    Wang W; Huang H; Guan Z
    Zhongguo Fei Ai Za Zhi; 2004 Oct; 7(5):414-8. PubMed ID: 21244794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer.
    Hirai K; Koizumi K; Haraguchi S; Hirata T; Mikami I; Fukushima M; Yamagishi S; Kawashima T; Okada D; Shimizu K; Kawamoto M
    Ann Thorac Surg; 2005 Jan; 79(1):248-53. PubMed ID: 15620951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinicopathological study on primary lung cancer--immunohistochemical expression of p53 suppressor gene and bcl-2 oncogene in relation to prognosis].
    Irie K; Ishida H; Furukawa T; Koyanagi K; Miyamoto Y
    Rinsho Byori; 1996 Jan; 44(1):32-41. PubMed ID: 8691638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers.
    Hou X; Li Y; Luo RZ; Fu JH; He JH; Zhang LJ; Yang HX
    Eur J Surg Oncol; 2012 Jun; 38(6):523-30. PubMed ID: 22440742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear and cytoplasmic p53 expression in pharyngeal squamous cell carcinoma: prognostic implications.
    Pukkila MJ; Kumpulainen EJ; Virtaniemi JA; Johansson RT; Halonen PM; Kellokoski JK; Kosunen AS; Nuutinen J; Kosma VM
    Head Neck; 2002 Aug; 24(8):784-91. PubMed ID: 12203805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers.
    Geradts J; Fong KM; Zimmerman PV; Maynard R; Minna JD
    Clin Cancer Res; 1999 Apr; 5(4):791-800. PubMed ID: 10213214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.
    Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Zhang J; Fu K
    Lung Cancer; 2008 Oct; 62(1):113-9. PubMed ID: 18550205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients.
    Lai CL; Tsai CM; Tsai TT; Kuo BI; Chang KT; Fu HT; Perng RP; Chen JY
    Clin Cancer Res; 1998 Dec; 4(12):3025-30. PubMed ID: 9865916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of the p53 family in lung cancer.
    Uramoto H; Sugio K; Oyama T; Nakata S; Ono K; Nozoe T; Yasumoto K
    Anticancer Res; 2006; 26(3A):1785-90. PubMed ID: 16827107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.